Clinical Trials Directory

Trials / Completed

CompletedNCT04976088

Clinical Trial With Diclofenac Sodium Medicated Plaster in Patients With Impact Injuries of the Limbs

Randomized, Double Blind, Parallel-groups, Non-inferiority Versus Flector® and Superiority Versus Placebo, Phase III Clinical Trial With Diclofenac Sodium 140 mg Medicated Plaster in Patients With Impact Injuries of the Limbs

Status
Completed
Phase
Phase 3
Study type
Interventional
Enrollment
214 (actual)
Sponsor
Fidia Farmaceutici s.p.a. · Industry
Sex
All
Age
18 Years – 65 Years
Healthy volunteers
Not accepted

Summary

Phase III, multinational, multicentre, randomized, prospective, double blind, parallel groups, placebo-controlled study to evaluate the analgesic effects of Test Diclofenac Sodium 140mg medicated plaster, Reference DIEP 180 mg medicated plaster, Flector® and Placebo plaster in patients with painful and phlogistic disease due to acute traumatic events of the limbs.

Detailed description

This will be a Phase III, multinational, multicentre, randomized, prospective, double blind, parallel groups, placebo-controlled study to evaluate the analgesic effects of Test Diclofenac Sodium 140mg medicated plaster (once a day), Reference DIEP 180 mg medicated plaster, Flector® (once a day) and Placebo plaster once a day (i.e. the placebo arm) in patients with painful and phlogistic (inflammatory response) disease due to acute traumatic events (injury/contusion) of the limbs.

Conditions

Interventions

TypeNameDescription
DRUGDiclofenac Sodium 140 mg medicated plasterTest product: Diclofenac Sodium 140 mg medicated plaster, topical application once a day
DRUGDiclofenac epolamine (DIEP) 180mg medicated plaster, FlectorReference product: Active-comparator, Diclofenac epolamine (DIEP) 180 mg medicated plaster, Flector®, topical application once a day
DRUGPlaceboPlacebo: Placebo plaster, topical application once a day.

Timeline

Start date
2018-05-25
Primary completion
2018-10-27
Completion
2018-10-27
First posted
2021-07-26
Last updated
2023-10-02

Locations

16 sites across 3 countries: Germany, Hungary, Italy

Source: ClinicalTrials.gov record NCT04976088. Inclusion in this directory is not an endorsement.